US based medical technology company Becton, Dickinson and Company (BD) has introduced its new cell sorter, the BD FACSMelody system to increase their existing portfolio of easy-to-use cell sorters.
Based on BD’s newly launched flow cytometers such as the BD Accuri C6 Plus and BD FACSCelesta systems, the BD FACSMelody system features simplicity in its design and is intended for benchtop use.
The device detects and isolates target cells for up to nine colours which is important for the identification of dim or rare subpopulations.
The cell-sorting procedure is assisted by the BD FACSChorus software which guides the researchers using an advanced automation technology.
The technology allows researchers to isolate two cell populations into separate tubes or deposit single or multiple target cells into 96- or 384-well plates at the same time.
BD worldwide biosciences president Claude Dartiguelongue said: "The BD FACSMelody system not only simplifies the entire operational process, but also has been designed to maximise cell population resolution and sort purity."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe BD FACSMelody cell sorting system is designed in six different configurations to cater to various application requirements ranging from a molecular biology lab isolating transfected cells with a single-color reporter gene to an immunology lab sorting a rare lymphocyte subset with a nine-color reagent panel.
The system features enhanced sensitivity and resolution by the optical fluidic alignment by a gel-coupled cuvette, which is designed to leverage the comprehensive BD Horizon Brilliant reagent portfolio.